Related Experiment Video
Updated: Jun 3, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Interleukin-18 promoter polymorphisms in patients with systemic lupus erythematosus
T Warchoł1, M Lianeri, M Olesińska
1Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Poznan, Poland.
Objectives:
The role of various polymorphisms located in the IL-18 promoter has not yet been defined with regards to patient susceptibility to SLE, and occurrence of clinical manifestations of the disease remains inconsistent.
Methods:
Using PCR-RFLP and DNA sequencing analysis we studied the frequency of -137 G/C (rs187238), -607 C/A (rs1946518) and -1297C/T (rs360719) polymorphisms in IL-18 promoter in patients with SLE from a sample of the Polish population.
Results:
We observed that patients with SLE bearing the IL-18 -1297CC genotype exhibited a 2.536-fold increased risk of SLE incidence (95% CI=1.333-4.826, p=0.0035). We also found a significantly higher frequency of the IL-18 -1297C allele in patients than in controls, with odds ratio (OR) for the IL-18 -1297C allele in patients with SLE being 1.558 (95% CI=1.189-2.041, p=0.0013). Moreover, there was an association between the IL-18 -1297CC genotype and renal manifestations of SLE, OR=3.792 (1.446-9.947, p=0.0051). However, we did not find any contribution of the IL-18 -607 C/A and -137 G/C polymorphisms to SLE incidence or occurrence of the studied SLE manifestations.
Conclusions:
Our findings confirmed that the IL-18 -1297C gene variant may contribute to the risk of SLE incidence. Moreover, IL-18 -1297CC might be associated with renal manifestations of SLE.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Non-LTR Retrotransposons
